HDAC9 and melanoma: Additionally, HDAC inhibitors have been previously shown to inhibit the expression of MITF [213], and combined with nivolumab in the treatment of advanced melanoma it achieved good ORR [214], and related clinical trials are under recruitment (NCT04674683).